- Home
- GROY vs TSHA Comparison
GROY vs TSHA Comparison
Compare GROY & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GROY | TSHA |
|---|---|---|
| Founded | 2020 | 2019 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.2B |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | GROY | TSHA |
|---|---|---|
| Price | $3.83 | $6.51 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | $5.90 | ★ $11.11 |
| AVG Volume (30 Days) | 2.3M | ★ 3.0M |
| Earning Date | 05-06-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 5.56 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $9,773,000.00 |
| Revenue This Year | $145.80 | N/A |
| Revenue Next Year | $60.03 | $1,228.40 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 17.28 |
| 52 Week Low | $1.43 | $1.46 |
| 52 Week High | $5.45 | $6.50 |
Technical Indicators
Market Signals| Indicator | GROY | TSHA |
|---|---|---|
| Relative Strength Index (RSI) | 54.22 | 77.02 |
| Support Level | $3.25 | $4.39 |
| Resistance Level | $3.83 | N/A |
| Average True Range (ATR) | 0.17 | 0.38 |
| MACD | 0.06 | 0.24 |
| Stochastic Oscillator | 79.46 | 90.94 |
Price Performance
Historical ComparisonAbout GROY Gold Royalty Corp.
Gold Royalty Corp is a precious metals-focused royalty and mineral streaming company. The company offers creative financing solutions to the metals and mining industry. The company's mission is to acquire royalties, streams and similar interests at varying stages of the mine life cycle to build a balanced portfolio offering near, medium and longer-term attractive returns for investors. It has its business as a single operating segment, being the investment in royalty and mineral stream interests. The company derives maximum revenue from Canada.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.